Rapamune, Sirolimus Newswire

Rapamune, Sirolimus Newswire

Comprehensive Real-Time News Feed for Rapamune, Sirolimus (generic).

Results 1 - 20 of 98 in Rapamune, Sirolimus (generic)

  1. Cures Within Reach Announces Winners of the 2017 Global Health Repurposing AwardsRead the original story w/Photo

    Monday Mar 20 | PR Log

    SKOKIE, Ill. - March 20, 2017 - PRLog -- Cures Within Reach, the leading global nonprofit focused on repurposing research as a fast track to saving patient lives, today announced the recipients of its 5th Annual Global Health Repurposing Awards.


  2. Comparing Stent Thrombosis associated with Zotarolimus Eluting Stents ...Read the original story w/Photo

    Wednesday Mar 15 | BioMed Central

    Two thousand fifteen has been a winning year for Drug Eluting Stents . Increase in the number of patients with cardiovascular diseases treated by Percutaneous Coronary Intervention has resulted to a high demand for second generation DES.


  3. REGiMMUNE Phase 2a Results Of RGI-2001, An Activator Of Invariant...Read the original story

    Thursday Mar 9 | BioSpace

    REGiMMUNE Corporation is pleased to announce the publication of its Phase 2a clinical trial results for RGI-2001, a novel liposomal formulation of a synthetic derivative of alpha-galactosylceramide, a naturally occurring ligand that binds to CD1d and activates invariant natural killer T cells . The company is developing RGI-2001 to ameliorate Graft versus Host Disease after allogeneic hematopoietic cell transplantation.


  4. MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in childrenRead the original story

    Thursday Mar 2 | British Journal of Cancer

    Primary melanoma of the CNS in children is extremely rare, and usually linked to congenital melanocytic naevus syndrome, caused by mosaicism for oncogenic NRAS mutations. Outcome is fatal in all cases.


  5. Sirolimus and secondary skin-cancer prevention in kidney transplantation.Read the original story

    Feb 23, 2017 | CiteULike

    Transplant recipients in whom cutaneous squamous-cell carcinomas develop are at high risk for multiple subsequent skin cancers. Whether sirolimus is useful in the prevention of secondary skin cancer has not been assessed.


  6. New Bioresorbable Vascular Scaffold from Meril, an Indian MultinationalRead the original story w/Photo

    Feb 22, 2017 | Medgadget

    Meril , a large Indian medical device firm, has developed a drug-eluting bioresorbable vascular scaffold, which looks like a stent but that eventually and slowly degrades is washed away by the body. The MeRes100 is made of PLLA coated with PDLLA, both biodegradable polymers, while Sirolimus , the immunosuppressant common in drug eluting stents, is embedded within the coating.


  7. Kinase targets in CNS drug discovery.Read the original story

    Feb 9, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Originally thought to be nondruggable, kinases represent attractive drug targets for pharmaceutical companies and academia.


  8. IQ4I Research & Consultancy Published a New Report on "Hernia...Read the original story

    Jan 26, 2017 | PR.com

    A hernia is the protrusion of organs or tissues through weakened or strained muscles that contain it. Among the various hernia types, the most common type occurs in the abdominal region.


  9. Model to Predict Disease Complexity and Costs Associated With AHCT in Acute LeukemiaRead the original story w/Photo

    Jan 23, 2017 | The American Journal of Managed Care

    Disease status, MUD/MRD donor, myeloablative conditioning regimen, GVHD prophylaxis other than tacrolimus/sirolimus, and Medicare and/or Medicaid as payer are significant predictors for cost of care in patient with acute leukemia who undergo allogenic hematopoietic cell transplant . , is denoted as the ratio of outcomes over cost.


  10. Pie Five hosts fundraiserRead the original story w/Photo

    Jan 18, 2017 | Mustang News

    Three-year-old Ellie was diagnosed with a very rare disease called Epithelioid Hemangioendothelioma, referred to as EHE on Ellie's GoFundMe page, last year after complaining of constant headaches in June, Ellie's uncle Austin Adkins said. She was originally diagnosed with swimmer's ear but as the pain progressed to the rest of her body Ellie was seen by an Otolaryngologist or an ear, nose and throat doctor.


  11. Researchers discover cancer treatment for transplant patientsRead the original story w/Photo

    Jan 18, 2017 | PhysOrg Weblog

    Kenar D. Jhaveri, MD, and Richard Barnett, MD, Feinstein Institute for Medical Research scientists and Northwell Health Department of Internal Medicine nephrologists, published a Letter to the Editor in the prestigious New England Journal of Medicine , which profiles a novel drug combination with the potential to help prevent rejection of a donor kidney in transplant patients undergoing cancer treatment. The novel drug combination allows the rapidly emerging cancer therapies called immune checkpoint inhibitors to be incorporated into a transplant patient's cancer treatment regimen.


  12. Removable airway stent could revolutionize surgeryRead the original story w/Photo

    Jan 12, 2017 | PhysOrg Weblog

    Erney Mattsson and colleagues experiment with a new kind of stent that can be removed after it has done its job. Credit: Stein Roar Leite, NTNU A knitted rag sock inspired this professor and MD to develop a stent that can easily be removed after it has done its job.


  13. OrbusNeich Release: Device Company Expands Portfolio With A Next...Read the original story

    Jan 10, 2017 | BioSpace

    Launch of Scoreflexa NC responds to cardiologists' need for a non-compliant scoring balloon in more resistant lesions OrbusNeich, a global company specializing in the provision of life-changing vascular solutions, has launched the Scoreflex NC, a non-compliant scoring balloon targeting more resistant lesions. Unique in the marketplace, the Scoreflex NC is a focused force dual-wire balloon system built to facilitate controlled plaque modification with strength and accuracy.


  14. Market Attractiveness Analysis - Organ Transplant Immunosuppressant...Read the original story w/Photo

    Jan 6, 2017 | SBWire

    The global organ transplant immunosuppressant drugs market exhibits a highly consolidated vendor landscape. The top five companies held more than 90% of the market in 2014.


  15. Revascularization of Unprotected Left Main Coronary Artery Disease:...Read the original story

    Dec 9, 2016 | Circulation

    From the Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Italy ; and Division of Cardiology, University of Florida College of Medicine, Jacksonville . From the Cardio-Thoracic-Vascular Department, Ferrarotto Hospital, University of Catania, Italy ; and Division of Cardiology, University of Florida College of Medicine, Jacksonville .


  16. Pharmaceutical Approval Update December 2016Read the original story

    Jul 29, 2016 | P&T Community

    Indication: Lisinopril oral solution is indicated for the treatment of hypertension in patients 6 years of age and older. It is also approved as adjunctive therapy for heart failure and to treat acute myocardial infarction .


  17. Micell Technologies Announces First Patient Enrolled In Landmark...Read the original story

    Nov 27, 2016 | BioSpace

    Candidates for trial participation suffer from symptomatic coronary artery disease, including those with chronic stable angina, silent ischemia, acute coronary syndromes and those who qualify for percutaneous coronary interventions. Enrollment is planned at approximately 10 clinical sites throughout "We are pleased to enroll the first patient in this important study," said Dr. Saito.


  18. Santen Pharma Announces Phase III Sakura Program Topline Results In...Read the original story w/Photo

    Nov 27, 2016 | BioSpace

    The SAKURA Program met its objective, demonstrating that OPSIRIA can effectively and safely reduce intraocular inflammation . Findings from SAKURA Study 1, the first Phase III trial, established the efficacy and safety of OPSIRIA as a potential treatment for non-infectious uveitis of the posterior segment.


  19. mTOR inhibitors for the treatment of severe congenital...Read the original story

    Nov 25, 2016 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Congenital hyperinsulinism is the commonest cause of persistent hypoglycemia in neonates and infants.


  20. Durham's Micell Technologies Nabs $26 MillionRead the original story

    Nov 20, 2016 | BioSpace

    Micell Technologies raised $25.8 million in a new round of equity and debt financing, according to an SEC filing posted this week. Micell currently produces the MiStent SES sirolimus eluting absorbable polymer coronary stent, designed to treat coronary artery disease.